www.businessinsider.com

www.businessinsider.com
Share

www.businessinsider.com

 •  October 17

Reuters Allergan, the drugmaker behind Botox, just had the patents on one of its key drugs invalidated. The case was regarding Restasis, a blockbuster eye drug whose patents Allergan had in September given to the Saint Regis Mohawk Tribe. The unusual move gave Restasis sovereign immunity. But on Monday, a judge from the district court of Eastern...

www.businessinsider.com

 •  October 11

Reuters In September, Allergan struck an unusual deal with the Saint Regis Mohawk Tribe to transfer patents of the eye drug Restasis, a move that gives the drug sovereign immunity from certain patent challenges. The goal is to protect the blockbuster drug from generic competition before its patents run out in 2024. Lawmakers aren't too happy about...

www.businessinsider.com

 •  October 5

The FDA on Tuesday approved a generic version of Copaxone, a drug that treats multiple sclerosis that generates about $4.2 billion in revenue. Shares of Teva Pharmaceuticals, which makes the branded version of Copaxone, fell by 11% on Wednesdsay, while Mylan, which makes the new generic version, was up as much as 18%. "Mylan has invested tens of...

www.businessinsider.com

 •  October 1

(Adds background, trade group comment) By Deena Beasley Sept 29 (Reuters) - A U.S. District Court judge on Friday cleared the way for Maryland to implement the nation's first law designed to penalize drugmakers for price gouging by denying the generic drug industry trade group's request for an injunction. The state's new law will go into effect as...

www.businessinsider.com

 •  September 26

Thomson Reuters The age of RNA interference drugs has arrived. Alnylam Pharmaceuticals announced positive results Wednesday from a closely watched phase 3 clinical trial of patisiran, the company’s lead drug designed to treat a rare nerve disorder known as familial amyloid polyneuropathy (FAP.) Most importantly, the safety profile of patisiran in...

www.businessinsider.com

 •  September 22

(Adds share price, details) Sept 21 (Reuters) - Impax Laboratories Inc is in talks to merge with privately held Amneal Pharmaceuticals LLC, the Wall Street Journal reported on Thursday, citing people familiar with the matter. The generic drugmaker's shares rose as much as 19.3 pct to $25.70, highest in nearly a year. Impax and Amneal are in talks...

www.businessinsider.com

 •  September 17

23andMe, a company known for its consumer genetics test, is also looking to develop new drugs. The company raised $250 million on Tuesday, and the funding will in part go toward drug development. While drug development and consumer genetics tests might seem like vastly different businesses, the link could be critical to finding new treatments for...

www.businessinsider.com

 •  September 15

The FDA just approved a version of Avastin, a blockbuster chemotherapy made by Genentech that brought in $6.7 billion in sales in 2016. The newly approved drug, made by Amgen, will go by the marketed name Mvasi. It's a type of medication called a "biosimilar." Biosimilars are a bit more complicated than your average competing medicine: Unlike...

www.businessinsider.com

 •  September 7

The legal challenges at Mallinckrodt, the drugmaker Wall Street loves to hate, are piling up. A former employee of the company is suing the company and its leadership, alleging they lied about its dependence on its controversial blockbuster drug, Acthar. The shares were bought as part of the company's stock purchase plan, so he's also suing on...

www.businessinsider.com

 •  September 6

Thomson Reuters (Reuters) - Patients taking Roche's targeted lung cancer drug Alecensa have a far lower risk of their disease spreading in the brain than those on Pfizer's Xalkori, new clinical trial data show. The results, which will be presented at the Sept. 8-12 European Society for Medical Oncology congress in Madrid, reinforce Alecensa's...